The balance between immune effector cells such as T cells and natural killer cells, and immunosuppressive Treg cells, dendritic, myeloid and monocytic sub-populations in the tumor microenvironment acts to calibrate the immune response to malignant cells. Accumulating evidence is pointing to a role for B cells in modulating the immune response to both solid tumors and hematologic cancer. Evidence from murine autoimmune models has defined B regulatory cell (Breg) subsets that express cytokines such as IL-10, TGF-β, and/or express immune regulatory ligands such as PD-L1, which can suppress T cell and/or natural killer cell responses. Multiple murine tumor models exhibit decreased tumor growth in B cell deficient or B cell depleted mice. In several of these models, B cells inhibit T cell mediated tumor immunity and/or facilitate conversion of T cells to CD4 + CD25 + FoxP3 + T regs, which act to attenuate the innate and/or adaptive antitumor immune response. Mechanisms of suppression include the acquisition of inhibitory ligand expression, and phosphorylation of Stat3, and induction of IL-10 and TGF-β, resulting in a Breg phenotype. Breg suppressive activity may affect diverse cell subtypes, including T effector cells, NK cells, myeloid derived suppressor cells (MDSC) and/or tumor associated macrophages. B cells may also directly promote tumorigenesis through recruitment of inflammatory cells, and upregulation of pro-angiogenic genes and pro-metastatic collagenases. Breg infiltration has now been identified in a variety of solid tumor malignancies including but not limited to ovarian, gastric, non-small cell lung cancer, pancreatic, esophageal, head and neck, and hepatocellular carcinomas. Increasing evidence suggests that recruitment of B cells and acquisition of suppressive activity within the tumor bed may be an important mechanism through which B cells may modulate innate and/or adaptive anti-tumor immunity. B cell depletion in the clinic using anti-CD20 antibodies and/or inhibitors of BTK and/or other signaling pathways, may be a useful strategy for augmenting the anti-tumor immune response.
Background
A subset of B cells identified as B-regulatory cells (Bregs) have recently emerged as major contributors to the pathogenesis of autoimmune and neoplastic disorders. In neoplastic disorders, Bregs are generated in response to signals from the tumor microenvironment and in turn promote tumor growth through interactions with Tregulatory cells (Tregs), myeloid-derived suppressor cells (MDSC), tumor-associated macrophages, CD4 + and CD8 + T lymphocytes, natural killer (NK) cells, and direct interactions with tumor cells. A role for B cells in anti-tumor immunity was first established by Brodt and Gordon [1] and Monach et al. [2] , who demonstrated that tumor growth was diminished in B-cell depleted mice. Qin et al. [3] and Shah et al. [4] later demonstrated that B cells inhibit CTL-mediated tumor immunity. More recently Olkhanud et al. [5] and Tadmor et al. [6] showed that Bregs may facilitate the conversion of CD4 + CD25
− T cells to CD4 + CD25 + FoxP3 + Tregs, which in turn attenuate the innate anti-tumor cellular immune response.
Effects of Breg cells in murine tumor models suggested that similar B regulatory activity would also be identified in human tumors. While some studies suggest that tumor-infiltrating B cells have a protective role against disease progression [7] [8] [9] [10] [11] [12] , other studies suggest that Bregs are upregulated in patients with solid tumor malignancies and are associated with enhanced tumoraggressiveness and poorer prognosis [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . In human lymphoid malignancies, malignant B cells appear to act as Bregs by suppressing the anti-tumor cellular immune response through expression of suppressive ligands [26] [27] [28] [29] . This has led to successful targeting of B-regulatory functions of malignant B cells in lymphomas, which have thus far shown remarkably favorable outcomes in several clinical trials [26] [27] [28] . These results have lent credence to the notion that Breg activity may be modulating immune responses against non-lymphoid solid tumors. Bregs have now been identified in humans with a variety of solid tumor malignancies including ovarian, gastric, lung, colorectal, pancreatic, breast, esophageal, bladder, squamous cell, and hepatocellular carcinomas [13-22, 24, 25] . These observations suggest that targeting of Breg activity may be used to enhance immunotherapeutic outcomes.
Breg subtypes in autoimmune disease and cancer 
FoxP3
+ Treg generation, and suppression of the release of macrophage-and monocyteproduced inflammatory cytokines [30] [31] [32] [33] . B cells with regulatory function were initially described in murine models of autoimmune diseases such as experimental autoimmune encephalitis (EAE), collagen-induced arthritis (CIA), and inflammatory bowel disease (IBD), in which B cell deficient mice developed severe nonremitting disease that was ameliorated with B cell adoptive transfer [15] [16] [17] [18] [19] [20] [34] [35] [36] [37] [38] [39] . Fillatreau et al. [36] showed that mice which had recovered from EAE produced IL-10 in response to autoantigen, while mice incapable of producing IL-10 developed severe non-remitting EAE. Mice with IL-10 deficiency restricted to B cells also developed severe non-remitting EAE, which could be ameliorated through the adoptive transfer of IL-10-producing B cells from wild type (WT) mice that had recovered from EAE. CD40-CD40L interaction was recognized as an essential step in the generation of IL-10-producing B cells in response to autoantigen [36] . This and similar results in other mouse autoimmune models [32] [33] [34] [38] [39] [40] [41] [42] implicated IL-10 as a principal effector of B cell immuneregulatory activity. Decreased frequency and dysfunction of IL-10 + Bregs have been described in humans with various autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), inflammatory bowel disease, graft-versus-host disease, and vasculitides [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] . Enhancement of peripheral and organ-specific Bregs has been shown to be protective in patients with severe acute pancreatitis [53] but also has been associated with advanced histological fibrosis stages in patients with chronic hepatitis B virus infection [54] , suggesting that Breg-mediated immune suppression may be beneficial in acute inflammatory states but harmful in chronic infectionmediated inflammatory states.
II.) Phenotypic markers of Bregs
In early mouse studies, IL-10 production was shown to be restricted mainly to a CD1d hi CD5 + ("B10") subset that comprised roughly 1-3 % of splenic B cells [37, 38] . Other phenotypically distinct B cell subsets identified in humans exhibit immune regulatory properties through both IL-10 dependent and independent mechanisms. Iwata et al. [25] showed that IL-10-producing B cells in humans were predominantly found within a CD24 hi CD27 + subset that was capable of suppressing monocyte cytokine production in vitro. Blair et al. [44] demonstrated that human CD19
hi peripheral blood B cells suppressed CD4 + T cell IFN-γ and TNF-α production in vitro, with suppressive activity that was dependent on IL-10, CD80, and CD86. The latter two membrane proteins are key ligands for CTLA-4, a co-inhibitory immune checkpoint receptor expressed on activated effector T cells and Tregs [53, 55] . CD19 +
CD25
hi B cells have also been suggested to represent a Breg population in humans with the capability of suppressing CD4 + T cell proliferation and enhancing CTLA-4 and FoxP3 expression on Treg cells in vitro, in a manner dependent on TGF-β but not IL-10 [56] . CD5 + B cells have also been implicated in the suppression of anti-tumor immunity in humans through activation of Stat3 [57] , a transcription factor that may be involved in production of IL-10 [58] .
Additional B cell expressed surface antigens have been shown to confer regulatory properties. Programmed Death 1 Ligand (PD-L1) interacts with PD-1 on T cells to induce tolerance and limit effector T cell responses [59] , and has recently shown to be expressed on human malignant B cells in several types of lymphoma including diffuse large B cell lymphoma (DLBCL), Hodgkin's lymphoma, and follicular lymphoma [26] [27] [28] . Fas-Ligand (FasL), a member of the tumor necrosis factor pathway, interacts with its receptor FasR (CD95) to initiate a signaling cascade leading to apoptosis. B cell expressed Fas-L has been implicated in the induction of T H cell apoptosis in HIV and EBV infections [60] , and Fas-L expression on malignant B cells in lymphoid cancers such as chronic lymphocytic leukemia (CLL) may play a role in inhibiting anti-tumor responses by inducing T H cell apoptosis [61] . Lindner et al. demonstrated that human Granzyme B-producing (GrB + ) B cells are induced by IL-21-secreting T cells, which in turn function to suppress T cell proliferation via GrB-dependent degradation of the T cell receptor (TCR)-ζ-chain in vitro. GrB + Bregs and adjacent IL-21-producing T cells were found in the microenvironment of several human tumors including breast, ovarian, cervical, colorectal, and prostate tumors [62] . These findings suggest that IL-21-dependent GrB Several murine tumors including the MC38 colorectal cancer, EL4 thymoma, and EMT-6 mammary carcinoma models demonstrate reduced or absent growth in B-cell deficient mice (BCDM) compared to WT mice [4, 6, 63] . The anti-tumor effect conferred by B cell deficiency in all three models was associated with increased T cell and NK cell infiltration and more vigorous Th1 cytokine and cytolytic T cell responses, and in EMT-6 was also associated with decreased proliferation of CD4 + FoxP3 + Tregs. Adoptive transfer of B cells from WT mice into tumorbearing BCDM restored tumor growth and Treg proliferation and diminished CD8 + IFN-γ + and NK cell infiltration into the tumor bed. Interestingly, in contrast to several autoimmune models the adoptive transfer of either WT or IL-10 −/− B cells was capable of rescuing tumor growth in the EMT-6 model [63] . In the MC38 model, adoptive transfer of OX40L −/− B cells was less efficient in rescuing tumor growth than WT B cell transfer, demonstrating a role for cognate interactions between OX40L and OX40 on B cells and T cells respectively in modulating the anti-tumor response [64] .
Pulmonary metastasis of murine 4 T1 breast cancer requires inactivation of antitumor NK cells and expansion of Treg cells [5, 65] . Olkhanud et al. [5] [5, 66] .
II) Bregs impair antigen-specific anti-tumor vaccines through suppression of T and NK cell responses
Consistent with B regulatory cells having an immunesuppressive function, antigen-specific anti-tumor vaccines have been demonstrated to be more effective in the absence of B cells in several mouse tumor models. In the B16 melanoma mouse model, vaccination against either of the tumor-associated antigens (TAA) gp100 or TRP-2 using adenovirus-based vectors suppressed tumor growth in B-cell deficient, but not WT mice. The enhanced antitumor response against B16-associated tumor antigens in BCDM was dependent on the presence of NK cells [67] . In EL-4 thymoma implanted mice, Oizumi et al. [68] demonstrated using a highly immunogenic secreted form of gp96 heat shock protein as a vaccine, that effective tumor antigen-specific gp96-chaperone vaccination was achieved with a single vaccination in BCDM, while repeated vaccinations were required to achieve a similar level of immunity in WT mice. Increased CD8 + cytotoxic responses directed against EL-4-associated tumor antigens were observed in vaccinated BCDM compared to vaccinated WT mice. These results indicated that inhibition of effects mediated by immune-suppressive Breg cells may help maximize anti-tumor responses induced by vaccination.
III) Tumor-infiltrating B cells acquire LAP/TGFβ and PD-L1 expression and suppress T and NK cell responses EMT-6 mammary tumors are rejected or show markedly diminished growth in BCDM but growth is restored in BCDM reconstituted with B cells [63] . Using the EMT-6 model Zhang et al. [69] demonstrated that tumor-infiltrating B cells (TIL-B) develop increased expression of LAP/TGF-β, CD80, CD86, and PD-L1 in vivo compared to splenic B cells. Development of a similar B cell immunosuppressive phenotype also occurred when B cells were co-cultured in vitro with EMT-6 cells, and was dependent on direct physical B cell: tumor cell contact. Functionally, these TIL-B cells demonstrated greater ability to suppress CD4 + and CD8 + T cell proliferation in response to anti-CD3/anti-CD28 costimulation, and also markedly suppressed NK cell proliferation in response to IL-15 compared to splenic B cells. Monoclonal antibodies directed against TGF-β or PD-L1 dramatically suppressed EMT-6 tumor growth in WT mice, suggesting a potential therapeutic strategy for targeting this specific B cell subpopulation. In addition, TIL-B but not splenic B cells were capable of secreting IL-10 following stimulation, suggesting that an IL-10 secreting subpopulation was predominantly contained within the TIL-B population. These results point to the local acquisition of immunosuppressive properties by B cells migrating into the tumor bed through intimate contact with the tumor cells. Mechanism(s) underlying this functional transition and migration, as well as evidence for similar activity in human tumors are being actively investigated.
IV) T2-MZP B cells accumulate in tumor-draining lymph nodes and promote metastasis independently of IL-10 B16-F10 melanoma grows significantly more slowly, but is not completely rejected in BCDM relative to WT mice [4] . Marked B cell accumulation in tumor-draining lymph nodes (TDLN) of mice implanted with B16-F10 melanoma tumors precedes the development of metastases. Ganti et al. [70] showed that T2-MZP (B220 MDSCs are key regulators of tumor growth and metastasis in the tumor microenvironment [71] . Using the B16 melanoma model in which tumor growth is inhibited in BCDM but restored with adoptive B cell transfer, Bodogai et al. [72] showed that adoptive transfer of MDSCs from B16-implanted WT mice into tumorbearing BCDM restored tumor growth to the same degree as did adoptive transfer of B cells from B16-implanted WT mice. Conversely, adoptive transfer of MDSCs from B16-implanted BCDM into tumor-bearing BCDM did not restore metastasis.
In human cell lines, myeloid cells sort-purified from healthy donor PBMCs depleted of T and NK cells and treated with CM from MDA-MB-231 breast cancer cells were able to suppress T-cell proliferation in vitro. However, myeloid cells from donor PBMCs depleted of T, NK, and B cells and treated with cancer-derived CM failed to suppress T cell proliferation.
These results indicate that the immune-suppressive and tumor-promoting functions of MDSCs may be acquired through "education" by Bregs. The nature of B cell mediated education of MDSC is unclear, but clearly indicates a role for Breg in modulating myeloid suppressor cell activity, in addition to aforementioned effects on T and NK cells, thereby shaping the overall immune microenvironment. JSI-124 (cucurbitacin I), a potent Stat3 inhibitor, also inhibited growth of 4 T1 murine tumors. 4 T1-implanted mice treated with JSI-124 suppressed tumor growth compared to non-treated mice, and B cells isolated from treated mice had decreased expression of Stat3. Consistent with the hypothesis that inhibition of B cell-expressed Stat3 was responsible for the anti-tumor effect of JSI-124, Stat3 low B cells from treated mice exhibited a tumor-suppressive effect when injected into 4 T1-bearing mice, while injection of Stat3 high B cells from non-treated mice promoted tumor growth [74] .
Yang et al. [75] showed that increased tumor growth mediated by Stat3 expression in B cells was associated with increased tumor angiogenesis. In T-and B-cell deficient +/+ B cell adoptive transfer was associated with increased tumor angiogenesis in vivo by Matrigel assay and in vitro in B cell: endothelial cell co-culture assays, and increased expression of pro-angiogenic genes by RNA in vivo. TIL-B cells with persistently-activated Stat3 has also been identified in several human tumors including melanoma, gastric, lung, liver, and prostate cancers [75] . Furthermore, Stat3 activity in human tumor tissues was associated with increased density of TIL-B cells and significantly increased intratumoral angiogenesis.
Zhang et al. [57] recently showed that CD5 positivity among CD19 cells strongly correlated with levels of Stat3 expression in human lung and prostate tumor tissues and in corresponding TDLN, indicating that Stat3-expressing Bregs may be contained within a CD5 + B cell population in human tumors.
Collectively these studies indicate an important role for Stat3 in conferring an immunosuppressive phenotype to Breg cells, mediated in part through local elaboration of TGF-β and through the induction of pro-angiogenic gene expression. Inhibition of Stat3 signaling may therefore be a useful means of reducing or reversing Breg promotion of tumor growth.
VII) CD19
± CD1d high CD5 ± Bregs infiltrate pancreatic neoplasms and mediate tumor growth via IL-35 signaling Pylayeva-Gupta et al. [76] recently showed that prominent B cell infiltrates are frequently present in human pancreatic intraepithelial neoplasia (PanIN) and in pancreata of mice harboring Kras-driven pancreatic neoplasms. In addition, implantation of pancreatic ductal epithelial cells expressing oncogenic Kras (Kras G12D ) into WT mice pancreata leads to infiltration of B cells adjacent to the newly developing tumor. Kras G12D pancreatic tumor growth is diminished in BCDM but tumor growth is restored following B cell adoptive transfer, which is accompanied by de novo tumor infiltration with the adoptively transferred B cells.
Since the CD1d hi CD5 + B cell population has been shown to mediate immune-suppression via IL-10 secretion [37, 38] and IL-35 [77] [77] . IL-35 has also been shown to promote growth of human pancreatic cancer cells in vitro [78] , and has been shown to be upregulated in the sera of patients with pancreatic cancer [79] . Together, these results suggest that B cells may infiltrate pancreatic neoplasms and promote tumor growth via suppression of antitumor immunity through IL-35 secretion. IL-35 mediated Breg suppression of tumor immunity may also be a suitable target for therapeutic intervention in select human tumors.
VIII) Bruton's tyrosine kinase (BTK) expression in B cells and macrophages, as a target for regulation of immune-suppressive phenotypes
Previous findings by Affara et al. [80] and Andreu et al. [81] suggested that TIL-B cells promote tumor growth in squamous cell carcinoma (SCC) models through interactions with Ig receptor FcRγ + myeloid cells and subsequent repolarization of TAM towards an immunesuppressive type ("M2"-type). Gunderson et al. [82] showed that mouse PDAC tumors were heavily infiltrated with B cells and FcRγ + myeloid cells, and furthermore that tumor growth was diminished in BCDM and Ig-receptor null FcRγ −/− mice. Based on these observations, investigators hypothesized that signaling pathways common to both B cells and macrophages, such as BTK signaling, may be involved in the suppression of antitumor immunity by infiltrating lymphocytes in PDAC tumors. In accordance with this hypothesis, activated BTK (pBTK) was identified in murine PDAC tumors in single-cell suspensions and was most prominent in CD19 + B cells and CD11b + myeloid cells. In in vitro assays using PDAC-derived B cells cocultured with macrophages, PDAC-derived B cells enhanced macrophage expression of Th2 cytokines. In contrast, the pre-treatment of PDAC-derived B cells with the BTK inhibitor ibrutinib instead enhanced macrophage expression of Th1 cytokines. These results indicate that inhibition of BTK in tumor-infiltrating B cells may promote macrophage repolarization from an immune-suppressive, tumorigenic M2-type toward a pro-inflammatory, anti-tumor M1-type.
In vivo, early stage PDAC tumor-bearing mice treated with ibrutinib exhibited significantly diminished tumor growth. Treatment of late-stage tumor-bearing mice treated with ibrutinib plus gemcitabine resulted in significantly diminished tumor growth compared to gemcitabine alone. BTK may therefore represent a novel potential target for reduction of Breg cell activity in cancer, and furthermore BTK inhibition may augment the efficacy of chemotherapy.
Ibrutinib has recently been approved by the FDA for treatment of patients with refractory or p53-mutated CLL [83] , as well as patients with relapsed mantle cell lymphoma [84] . These findings have provided a rationale for clinical trials examining the use of ibrutinib as adjunctive therapy to gemcitabine and nab-paclitaxel in metastatic pancreatic carcinoma (NCT02562898, NCT02436668).
IX) A link between 4-1BBL expression on B cells and the generation of cytotoxic Granzyme-B + T cells
Interestingly, depletion of B cells with an anti-CD20 antibody (α-CD20 mAb) in WT mice prior to inoculation with 4 T1 cells blocked metastasis of 4 T1 tumor, consistent with findings observed in genetically B-cell deficient mice [85] . However, administration of α-CD20 mAb to WT mice with established 4 T1 tumors unexpectedly resulted in significantly enhanced tumor growth and metastasis.
Bodogai et al. [85] reconciled this paradoxical result by demonstrating that α-CD20 mAb treatment of 4 T1 tumor-bearing mice enriches for B cells that are phenotypically CD20 low and have enhanced T cell-suppressive effects ex vivo compared to B cells from control IgG2a-treated tumor-bearing mice. Consistent with these findings in mice, co-culture of human peripheral blood B cells with human breast cancer or colon cancer cells resulted in emergence of a CD20
low Breg population that suppressed T-cell activity and was sustained after treatment with α-CD20 mAb in vitro.
Screening for TLR ligands capable of inactivating Bregs revealed that the TLR9 ligand CpG-ODN was able to upregulate CD20 and block the T cell-suppressive effects of human and murine tBregs in vitro. Treatment of 4 T1 tumor-bearing mice with CpG-ODN abrogated lung metastasis, and ex vivo B cells derived from CpG-ODN treated tumor-bearing mice induced T cell proliferation and expansion of GrB + CD8 + cytolytic T cells. Enhancement of metastasis by α-CD20 mAb treatment was completely reversed in vivo when α-CD20 mAbtreated tumor-bearing mice were adoptively transferred with CpG-ODN-pretreated B cells from syngeneic naïve mice. In contrast, adoptive transfer of mock-treated B cells minimally reduced the enhanced lung metastasis following α-CD20 mAb treatment.
4-1BBL (CD137L) is an immune co-stimulatory receptor and a member of the TNF receptor family, which activates CD8 + T cells and NK cells via cross-linking of 4-1BB (CD137) expressed primarily on T cells [86] . Bodogai et al. [85] investigators observed that human and murine CD20
low Bregs also had reduced 4-1BBL expression compared to normal B cells. Treatment with CpG-ODN reversed the reduced expression of 4-1BBL on murine and human Bregs in vitro as well as in vivo in tumor-bearing mice, resulting in emergence of a CD20 high 4-1BBL high B cell subset. Consistent with the results seen in the 4 T1 murine model, the depletion of B cells using α-CD20 mAb in mice inoculated with EMT-6 did not result in tumor rejection as expected, and was associated with a paradoxical increase of CD4 + FoxP3 + Tregs in the spleens of treated mice, although a role for 4-1BBL was not investigated in the EMT-6 model [63] .
These results suggest that tumors can induce a population of CD20 low 4-1BBL low immune-suppressive Bregs that are relatively enriched following α-CD20 mAb treatment. Relative enrichment of CD20 low 4-1BBL low Bregs therefore is a plausible explanation for the failure of rituximab to provide a clinical benefit when combined with IL-2 immunotherapy for patients with renal cell carcinoma and melanoma [87] . Treatment strategies directed toward facilitating the conversion of 4-1BBL + by oxaliplatin and was associated with increased tumoral CTL density and IFN-γ production, thus implicating TGF-β signaling in the generation of this Breg subpopulation. Large MC tumors resistant to treatment with oxaliplatin monotherapy showed diminished tumor growth when treated with oxaliplatin plus anti-PD-L1, but not with anti-PD-L1 alone.
In human prostatectomy samples, CD8 + and CD20 + cell density was higher in patients with PC compared to healthy controls, and correlated significantly with advanced stage and treatment failure [88] . IL-10-producing IgA + CD138 + plasma cells were also present in human PC samples but were more abundant in metastatic PC and therapy-resistant PC compared to early stage disease.
These results indicate that treatment with an immunogenic chemotherapeutic agent, oxaliplatin, may induce a CD138 + IgA + PD-L1 + IL-10 + Breg population generated via a TGFβ-dependent pathway that limits the effectiveness of oxaliplatin by inhibiting intratumoral CTL infiltration. This further suggests that the successful treatment of large prostate tumors with oxaliplatin may require the elimination of these immunosuppressive IgA + plasma cells that are present in both mouse and human PC, and suggests a rational approach to augmenting beneficial chemotherapy effects on the anti-tumor immune response. Targeting of the PD-L1/PD-1 axis may be an especially useful strategy in this regard.
A summary of reported B reg phenotypic markers and functional attributes is presented in Table 1 , and several of the key reported interactions reviewed above are schematically represented in Fig. 1 .
B cell effects on carcinogenesis

I) B cells are involved in de novo carcinogenesis in murine models of inflammation-associated squamous cell carcinoma
Several landmark studies also point to a role for B cells in facilitating carcinogenesis, mediated through effects on local inflammation [80, 81, 89, 90] . In the K14-HPV16 (HPV16) transgenic mouse model of inflammationassociated de novo epithelial carcinogenesis, the absence of T-and B-lymphocytes (generated by intercrossing with Rag1 −/− mice) limits immune cell infiltration and attenuates characteristic markers of premalignancy such as VEGF-A activity, matrix metalloproteinase activity, epithelial hyperproliferation, and development of angiogenic vasculature [89] . Subsequently, neoplastic progression is abrograted in HPV16/Rag1 −/− mice. Premalignant HPV16 skin was characterized by enhanced immunoglobulin (Ig) deposition, suggesting that B cells initiate Ig deposition into neoplastic tissue, paralleling inflammation and premalignant progression in HPV16 mice. Accordingly, skin from HPV16/Rag1 −/− mice had diminished Ig deposition and reduced immune cell infiltration. Adoptive transfer of B cells or serum, but not T cells from HPV16 mice into HPV16/Rag1 −/− mice restored Ig deposition, innate immune cell infiltration and premalignant characteristics and facilitated progression to epithelial carcinogenesis.
Based on these findings, Affara et al. [80] showed that B cell depletion with α-CD20 mAb restricted premalignant progression in K14-HPV16 transgenic mice. In contrast, α-CD20 mAb treatment did not affect growth of SCC tumors derived from K14-HPV16 mice that were orthotopically implanted into syngeneic WT mice. However, α-CD20 mAb treatment in combination with the chemotherapy (CTX) agents cisplatin, carboplatin, or paclitaxel, each ineffective on their own, resulted in tumor regression in mice orthotopically implanted with SCC tumors. Further analysis revealed that combinatorial α-CD20 mAb/CTX treatment was associated with increased tumor CD8 + infiltration compared to CTX treatment alone. Similar to aforementioned findings in a mouse model of prostate cancer [88] , these results indicate the efficacy of augmenting chemotherapy with Bcell depletion strategies to improve outcomes.
Based on the findings implicating B cells in squamous carcinogenesis in mice [80, 89] , and other previous studies showing that TNF-α deficient mice are resistant to chemical carcinogenesis of the skin [91] , Schioppa et al. [90] investigators hypothesized that TNF-α might be involved in the tumor-promoting actions of B cells.
In a [81, 89] or local elaboration of TNF-α [90] , both leading to enhanced myeloid cell infiltration and reduced CD8+ T cell infiltration. Interestingly, B cell depletion with α-CD20 mAb was efficacious in suppressing tumor growth as an adjunct to chemotherapy in the squamous carcinoma mouse model [80] and was efficacious as monotherapy in a mouse model of pancreatic cancer [92] , however treatment with α-CD20 mAb accelerated tumor growth in mouse breast cancer models [64, 85] . Further investigations are warranted to determine how Breg induction may differ among tumor types and identify tumors that may be responsive to α-CD20 mAb treatment. CD19 + BTK+ In a mouse model of prostate cancer (myc-CaP), Ammirante et al. [93] demonstrated that castration of myc-CaP tumor-bearing mice results in the accumulation of an immune infiltrate comprised of B and T lymphocytes, NK cells, and myeloid cells in dying androgen-deprived primary tumors. This process precedes the emergence of castration-resistant prostate (CR-CaP) tumors. To further explore the role of tumorinfiltrating lymphocytes (TILs) in the emergence of CRCaP, irradiated WT mice were reconstituted with bone marrow (BM) derived from either WT or Rag1 −/− mice and then inoculated with myc-CaP tumors, followed by castration 8 weeks later. Both groups showed identical growth of the primary tumor, however CR-CaP tumor growth after castration was significantly delayed in mice reconstituted with Rag1 −/− BM compared to WT BM. More rapid emergence of CR-CaP was restored when irradiated mice were reconstituted with TCRβ −/− BM, however CR-CaP growth remained delayed when irradiated mice were reconstituted with J H −/− BM, indicating that elimination of B cells rather than T cells was responsible for delayed growth of CR-CaP. Further mechanistic analysis revealed that secretion of lymphotoxin (LT) by infiltrating B cells stimulates LTβR on CaP cells to induce nuclear translocation of IKKα and activation of STAT3, thereby driving androgen-independent tumor growth after castration. Inhibition of IKKα, STAT3, LTβR, as well as B cell-specific LTβ ablation were each independently capable of delaying CR-CaP growth. This study invokes a completely novel mechanism by which local elaboration of a cytokine by infiltrating B cells may indirectly stimulate tumor growth. The relationship between androgen deprivation and B cell mobilization is poorly understood. Whether similar pathogenesis will be seen in human castration-resistant prostate cancer is not known.
III) B cell recruitment is regulated by HIF1α stabilization
and promotes tumor growth in a murine model of pancreatic ductal adenocarcinoma Hypoxia, a central feature of the tumor microenvironment, drives the expression of hypoxia-inducible factors on tumor cells including HIF1α, which regulates expression of genes involved in metabolism, angiogenesis, cell survival, and inflammation [94, 95] . Lee et al. [92] showed that hypoxia-driven HIF1α expression and stabilization occurred in the early growth stages of both murine Kras G12D PDAC and human PDAC tumors, and that the deletion of pancreas-specific Hif1α in mice harboring Kras G12D tumors resulted in accelerated tumor growth and was associated with an influx of intrapancreatic B cells. Human PDAC tumors also showed significant intra-pancreatic B cell infiltration. B-cell depletion in Kras G12D /HIF1α-KO mice following treatment with α-CD20 mAb significantly decreased the number of grade 3 PanIN lesions and reduced the percentage of mice with microinvasive lesions, indicating that the accelerated tumor growth in HIF1α-KO mice is due at least in part related to increased intrapancreatic B-cell recruitment.
Increased secretion of the B-cell chemokine CXCL13 in HIF1α-KO mice was believed to be responsible for the prominent influx of intrapancreatic B cells, as CXCL13 levels by ELISA and immunohistochemical staining were significantly higher in Kras G12D /HIF1α-KO mice compared to Kras G12D and WT mice. CXCL13 protein accumulation was also detected in the majority of human PDAC tumor samples.
Together, these observations indicate that hypoxia may accelerate the growth of HIF1α-deleted PDAC tumors in part by augmenting intrapancreatic B-cell accumulation, which appears to be driven by local expression of the B cell chemokine CXCL13. Therefore HIF1α expression and stabilization may actually inhibit tumor B cell infiltration and thus may be a protective mechanism in response to tissue hypoxia. The effects of HIF1α signaling on local B cell recruitment represent a unique and unanticipated effect of hypoxia on the composition of tumor immune infiltrates and subsequent anti-tumor response.
IV) IV. B cells are actively recruited to bladder tumors
and promote tumorigenesis via secretion of IL-8
Ou et al. [22] demonstrated that human bladder cancer (BCa) tissues are capable of recruiting more B cells than surrounding normal bladder tissues. In turn, B cell infiltration in BCa tissues increases BCa cell invasiveness as demonstrated in in vitro chamber invasion assays using three separate human BCa cell lines cocultured with B cells. In addition, mice xenografted with human J82 BCa cells and co-implanted with B cells developed significantly more metastatic foci in vivo compared to mice implanted with J82 cells alone.
Increased expression of androgen receptor (AR) by tumor cells was associated with increased BCa invasiveness. AR signaling has been implicated in bladder carcinogenesis, as androgen deprivation has been shown to inhibit tumor growth in mouse models and xenografts [96] .
Further investigation revealed that B cells augment AR expression in human BCa tissue by secreting IL-8, a proinflammatory chemokine shown to promote bladder carcinogenesis and metastasis [97, 98] . In turn, increased AR expression leads to upregulation of the matrix metalloproteinases MMP1 and MMP13, mediators of extracellular collagen degradation with known roles in tumor invasion, metastasis, and BCa progression [98, 99] To date, most studies evaluating the prognostic significance of TILs have focused on T cells, while less attention has been devoted toward TIL-B cells. Using high resolution gene expression arrays, Schmidt et al. [11] showed that expression of a B cell "metagene" signature consisting of 60 genes in tumors from patients with node-negative breast cancer significantly correlated with metastasis-free survival. Tumor expression of the IgG + plasma cell marker immunoglobulin kappa C (IGKC) provided prognostic information that was comparable with that of the B cell metagene signature in breast cancer patients. IGKC expression was also associated with better prognosis in non-small cell lung cancer (NSCLC) and colorectal adenocarcinoma (CRC) cohorts [11] . In another cohort of patients with CRC, higher density of tumor CD20 + B cell infiltration as measured by immunohistochemistry (IHC) correlated significantly with improved overall survival [7] . This data suggests that an immune response may actually be mediated by B cells in the aforementioned examples.
Increased tumor infiltration of CD20 + B cells has also been shown to portend a better prognosis among patients with epithelial ovarian cancer (EOC). Nielsen et al. [100] demonstrated that CD20 + B cells co-localized with CD8+ T cells in tumor specimens from patients with high-grade serous ovarian cancer (HGSC), raising the possibility that TIL-Bs act as antigen-presenting cells to facilitate the antitumor T cell cytolytic response. Consistent with the hypothesis that TIL-Bs may have an antitumor effect when co-localized with CD8 + T cells, Kroeger et al. [10] showed that TIL-B-and T-cells colocalize and arrange in tertiary lymphoid structures (TLS) surrounded by dense IgG + plasma cell infiltrates in HGSC tumors. CD8 + TILs conferred a better prognosis only in the presence of adjacent CD4 + T cell TILs, CD20 + B cell TILs, and CD138 + plasma cells. Plasma cells adjacent to TLS may confer an anti-tumor effect via antibody-related mechanisms such as complement activation or antibody-dependent cellular cytotoxicity (ADCC) [10] .
In contrast to the above observations, other studies have demonstrated an increase in CD20
+ and CD138 + cell infiltration in association with a poorer prognosis. Lundgren et al. [8] demonstrated that in patients with EOC, increased tumoral CD20 + and CD138 + expression by IHC was associated with advanced tumor grade, and CD138 expression correlated significantly with reduced overall and cancer-specific survival. In patients with primary operable invasive ductal breast cancer, increased CD138 + B-cell infiltration was also independently associated with poorer recurrence-free survival [23] . In patients with prostate cancer, increased tumor CD20 + density correlated significantly with D' Amico high-risk categorization, and was predictive of treatment failure [24] . In addition, Prueitt et al. [12] showed that immunoglobin expression by TIL-B cells was increased in active smokers with PC, who are known to have a higher incidence of metastatic disease, compared to past or never smokers with PC.
Studies examining the prognostic significance and effects on anti-tumor immunity of tumor-infiltrating CD20 + B cells and CD138 + plasma cells have therefore yielded conflicting results. CD20 + B cells may function to present tumor antigen to cytotoxic T cells or other immune effector cells, and plasma cells may secrete antibodies that aid in the immune response against tumor cells [7, 10, 11, 100] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
In patients with esophageal cancer, frequencies of peripheral blood IL-10 + Bregs were significantly greater compared with healthy controls [17] . IL-10 + Breg frequency also correlated with clinical staging and disease progression in esophageal cancer patients, as higher frequencies were seen in the peripheral blood of patients with Stage III/IV disease compared to early stage disease patients [17] .
Wei et al. [16] [21] .
Increased peripheral blood IL-10 + Bregs were observed in patients with NSCLC compared to healthy controls, and increased peripheral IL-10 + Bregs in NSCLC patients correlated with an increase in peripheral FoxP3 + Tregs and MDSCs [18] . Furthermore, increased peripheral IL-10 + Breg frequency was associated with more aggressive disease progression and advanced stage. While Zhou et al. [14] also identified increased frequency of peripheral Bregs in lung cancer patients versus controls, they unexpectedly also showed decreased frequency of peripheral Tregs, but speculated that lung tissues might show increased Tregs.
In tumor specimens from patients with hepatocellular cancer (HCC), the prevalence of intrahepatic B cells at the tumor margin was associated with tumor-invasive features [19] . high Bregs which produced IL-10 upon interaction with PD-L1 or anti-PD1 antibody. Increased tumor infiltration with PD-1 high IL-10-producing Bregs was associated with reduced number and dysfunction of CD8 + cells. These findings identify a uniquely suppressive PD-1 + B cell subset in HCC pathogenesis. Therefore, PD-1 may also be viable target for the reduction of Breg activity in HCC [15] .
These studies suggest that frequencies of B cells with regulatory phenotypes are increased in the peripheral blood of patients with various solid tumor types compared to age-matched controls. Also, there is evidence that B cells with regulatory phenotypes accumulate in the tumor tissues and peri-tumoral environment. It is not clear if Bregs are actively promoting tumor growth in humans or if an increase in Bregs is merely an immune response against the tumor, however aforementioned ex vivo and xenograft assays demonstrating suppressive properties of Bregs gives credence to the former hypothesis.
Conclusions
It has become clear that in both mouse models and in humans that B cells can mediate immunosuppression through modulation of innate and/or adaptive immune responses in support of tumor growth. In several murine model systems B cells are actively recruited to tumors and directly acquire suppressive activity within the tumor bed [69] . Signaling through diverse pathways such as BTK, NF-kB and/or STAT3 has been implicated in the generation of the Breg phenotype.
A variety of cytokines secreted by Bregs have been implicated in the suppression of anti-tumor immunity including IL-10, IL-35, IL-6, and TGF-β. Additionally, Bregs may express a variety of suppressive ligands including PD-L1, PD-1, CD80, CD86, LAP-TGF-β, Fas-L, CD40L, and OX40L. Bregs may also express proteases such as Granzyme-B that directly impair T cell function [62] .
Bregs may support expansion of suppressive Tregs and MDSCs, suppress stimulatory Th 1 /Th 17 cells, promote skewing of T-helper cells and macrophages toward suppressive Th 2 /M2 types, and/or may interact directly with effector CD4 + and CD8 + T cell and/or NK cells to suppress anti-tumor immunity.
B cells may also directly promote carcinogenesis through local elaboration of inflammatory mediators such as TNF-α in squamous cell skin cancer [90] , lymphotoxin in prostate cancer [93] , and IL-8 in bladder cancer [22] . Antibody production and subsequent deposition of immune-complexes in tumor tissue is another mechanism whereby B cells may promote inflammation and neoplastic progression. B cells may also facilitate tumorigenesis through the upregulation of pro-angiogenic genes.
The list of human tumors infiltrated with B cells is rapidly expanding. B cell infiltration of tumors has been associated with improved prognosis or alternatively with enhanced tumor aggressiveness in different studies. Studies examining B cells with regulatory phenotypes however suggest uniformly that Breg infiltration may enhance tumor progression.
B cell depletion can be accomplished using α-CD20 mAb such as rituximab and obinatuzumab, or through use of inhibitors of signal transduction such as ibrutinib.
B cell depletion strategies deployed in combination with current immune therapies requires further study. Not all forms of B cell depletion may be equally effective, as demonstrated by the failure or limited effectiveness of α-CD20 mAb therapy in several tumor models. Further investigations are necessary to identify Bregspecific targets that may be selectively used to deplete key B cell subpopulations with regulatory function, and/ or to modulate B cell-T effector cell cross-talk through co-stimulatory ligands, cytokines, and/or chemokines to augment anti-tumor effector responses. 
